These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 38891886)

  • 21. Preclinical rationale for use of the clinically available multitargeted tyrosine kinase inhibitor crizotinib in ROS1-translocated lung cancer.
    Yasuda H; de Figueiredo-Pontes LL; Kobayashi S; Costa DB
    J Thorac Oncol; 2012 Jul; 7(7):1086-90. PubMed ID: 22617245
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Elevation of tumor mutation burden in ROS1-fusion lung adenocarcinoma resistant to crizotinib: A case report.
    Yang T; Xu R; Yan B; Li F; Liu H
    Medicine (Baltimore); 2018 Dec; 97(52):e13797. PubMed ID: 30593165
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical features of Bim deletion polymorphism and its relation with crizotinib primary resistance in Chinese patients with ALK/ROS1 fusion-positive non-small cell lung cancer.
    Zhang L; Jiang T; Li X; Wang Y; Zhao C; Zhao S; Xi L; Zhang S; Liu X; Jia Y; Yang H; Shi J; Su C; Ren S; Zhou C
    Cancer; 2017 Aug; 123(15):2927-2935. PubMed ID: 28346673
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment Patterns and Clinical Outcomes Among Patients With ROS1-rearranged Non-small-cell Lung Cancer Progressing on Crizotinib.
    De Giglio A; Lamberti G; Facchinetti F; Genova C; Andrini E; Dal Bello MG; Tiseo M; Metro G; Chiari R; Ricciuti B
    Clin Lung Cancer; 2020 Sep; 21(5):e478-e487. PubMed ID: 32409267
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Analysis of the status of EGFR, ROS1 and MET genes in non-small cell lung adenocarcinoma.
    Wang Q; Lv Y; Zhong M; Zhu F; Wei L; Shi H
    J BUON; 2017; 22(4):1053-1060. PubMed ID: 28952227
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Management of a patient with a double EGFR and MET anomaly by combined treatment].
    Jénot L; Rouquette I; Mazieres J
    Rev Mal Respir; 2020 Jun; 37(6):488-491. PubMed ID: 32430158
    [TBL] [Abstract][Full Text] [Related]  

  • 27. An EGFR-mutated Lung Adenocarcinoma Undergoing Squamous Cell Carcinoma Transformation Exhibited a Durable Response to Afatinib.
    Sato M; Matsui A; Shimoyama Y; Omote N; Morise M; Hase T; Tanaka I; Suzuki K; Hasegawa Y
    Intern Med; 2018 Dec; 57(23):3429-3432. PubMed ID: 30101911
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Epidermal Growth Factor Receptor (EGFR) Mutations and Anaplastic Lymphoma Kinase/Oncogene or C-Ros Oncogene 1 (ALK/ROS1) Fusions Inflict Non-Small Cell Lung Cancer (NSCLC) Female Patients Older Than 60 Years of Age.
    Ke L; Xu M; Jiang X; Sun X
    Med Sci Monit; 2018 Dec; 24():9364-9369. PubMed ID: 30580372
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A comprehensive analysis of clinical outcomes in lung cancer patients harboring a MET exon 14 skipping mutation compared to other driver mutations in an East Asian population.
    Gow CH; Hsieh MS; Wu SG; Shih JY
    Lung Cancer; 2017 Jan; 103():82-89. PubMed ID: 28024701
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Crizotinib with or without an EGFR-TKI in treating EGFR-mutant NSCLC patients with acquired MET amplification after failure of EGFR-TKI therapy: a multicenter retrospective study.
    Wang W; Wang H; Lu P; Yu Z; Xu C; Zhuang W; Song Z
    J Transl Med; 2019 Feb; 17(1):52. PubMed ID: 30791921
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Real-World Data on Combined EGFR-TKI and Crizotinib Treatment for Acquired and De Novo
    Urbanska EM; Grauslund M; Koffeldt PR; Truelsen SLB; Löfgren JO; Costa JC; Melchior LC; Sørensen JB; Santoni-Rugiu E
    Int J Mol Sci; 2023 Aug; 24(17):. PubMed ID: 37685884
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy of Pemetrexed-Based Chemotherapy in Patients with ROS1 Fusion-Positive Lung Adenocarcinoma Compared with in Patients Harboring Other Driver Mutations in East Asian Populations.
    Chen YF; Hsieh MS; Wu SG; Chang YL; Yu CJ; Yang JC; Yang PC; Shih JY
    J Thorac Oncol; 2016 Jul; 11(7):1140-52. PubMed ID: 27094798
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Clinical Outcomes of Different First-Line EGFR-TKIs Plus Bevacizumab in Advanced EGFR-Mutant Lung Adenocarcinoma.
    Huang YH; Hsu KH; Chin CS; Tseng JS; Yang TY; Chen KC; Su KY; Yu SL; Chen JJW; Chang GC
    Cancer Res Treat; 2022 Apr; 54(2):434-444. PubMed ID: 34352999
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.
    Sequist LV; Yang JC; Yamamoto N; O'Byrne K; Hirsh V; Mok T; Geater SL; Orlov S; Tsai CM; Boyer M; Su WC; Bennouna J; Kato T; Gorbunova V; Lee KH; Shah R; Massey D; Zazulina V; Shahidi M; Schuler M
    J Clin Oncol; 2013 Sep; 31(27):3327-34. PubMed ID: 23816960
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy of chemotherapy plus immune checkpoint inhibitors in patients with non-small cell lung cancer who have rare oncogenic driver mutations: a retrospective analysis.
    Yamaguchi T; Shimizu J; Matsuzawa R; Watanabe N; Horio Y; Fujiwara Y
    BMC Cancer; 2024 Jul; 24(1):842. PubMed ID: 39009968
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Response to Crizotinib After Entrectinib Resistance in
    Vaz VR; Gandhi MM; Ricciuti B; Alessi JV; Elkrief A; Ladanyi M; Vanderbilt C; Pecci F; Aldea M; Barrichello A; Saini A; Sholl L; Sands JM; Awad MM
    JCO Precis Oncol; 2024 Oct; 8():e2400394. PubMed ID: 39374479
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Complete metabolic response in a patient with repeatedly relapsed non-small cell lung cancer harboring ROS1 gene rearrangement after treatment with crizotinib.
    Bos M; Gardizi M; Schildhaus HU; Heukamp LC; Geist T; Kaminsky B; Zander T; Nogova L; Scheffler M; Dietlein M; Kobe C; Holstein A; Maintz D; Büttner R; Wolf J
    Lung Cancer; 2013 Jul; 81(1):142-3. PubMed ID: 23558310
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A case of ROS1-rearranged lung adenocarcinoma exhibiting pleural effusion caused by crizotinib.
    Tachi H; Nishino K; Nakaizumi T; Kuramoto K; Shimizu K; Yamamoto Y; Kobayashi K; Ichimura H; Sakata A; Nawa T
    Thorac Cancer; 2020 Jul; 11(7):2063-2066. PubMed ID: 32433811
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Biomarker guided treatment in oncogene-driven advanced non-small cell lung cancer in older adults: A Young International Society of Geriatric Oncology report.
    Christofyllakis K; Monteiro AR; Cetin O; Kos IA; Greystoke A; Luciani A
    J Geriatr Oncol; 2022 Nov; 13(8):1071-1083. PubMed ID: 35525790
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Therapeutic strategies for afatinib-resistant lung cancer harboring HER2 alterations.
    Torigoe H; Shien K; Takeda T; Yoshioka T; Namba K; Sato H; Suzawa K; Yamamoto H; Soh J; Sakaguchi M; Tomida S; Tsukuda K; Miyoshi S; Toyooka S
    Cancer Sci; 2018 May; 109(5):1493-1502. PubMed ID: 29532558
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.